Moberg Pharma Q4’2023: Lots of progress in a short time - Redeye

Redeye sees the end-of-year report as results as uneventful. More important were the indications of a good start to the Swedish launch, the conclusion of the enrollment to the Phase 3 study, and progress regarding the Terbinafine supply. These factors are essential next steps for Moberg Pharma’s commercialization of MOB-015. The national approvals in the remaining countries in the DCP process are in process and will be approved.

Länk till analysen i sin helhet: https://www.redeye.se/research/978861/moberg-pharma-q42023-lots-of-progress-in-a-short-time?utm_source=finwire&utm_medium=RSS